Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
OMI 0.315 +0.0% BMM 3.80 +0.0% CGD 0.630 +10.5% OCG 0.275 −1.8% CAMB 0.980 −2.0% HMR 0.610 −1.6% GOFL 0.025 +0.0% SIG 1.02 −1.0% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.400 +0.0% LIB 0.800 −12.1% SMY 0.290 +23.4% SAG 1.02 +0.0% OMI 0.315 +0.0% BMM 3.80 +0.0% CGD 0.630 +10.5% OCG 0.275 −1.8% CAMB 0.980 −2.0% HMR 0.610 −1.6% GOFL 0.025 +0.0% SIG 1.02 −1.0% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.400 +0.0% LIB 0.800 −12.1% SMY 0.290 +23.4% SAG 1.02 +0.0%
Earnings

NEUPATH HEALTH REPORTS FOURTH QUARTER AND YEAR-END 2025 RESULTS

By The Northwire Desk — AI Analysis Mar 26, 2026 · 07:30 NPTH · 0.48 Neupath Health Inc.
NPTH · Price

Executive Summary

  • NeuPath Health reported Q4 2025 total revenue of C$22.1 million, a 17% YoY increase, and full‑year revenue of C$87.2 million, up 20% YoY.
  • Adjusted EBITDA reached C$1.0 million for the quarter (up 9% YoY) and C$6.0 million for the year (up 56% YoY), marking the company’s 28th consecutive quarter of positive Adjusted EBITDA.
  • The company announced a grant of 295,000 stock options and 651,000 restricted share units to two officers, effective March 31 2026, and scheduled an investor webinar for Thursday, March 26 2026 at 10:00 AM ET / 7:00 AM PT.

Key Details

  • Quarterly Revenue: C$22.1 million (Q4 2025) vs. C$18.9 million (Q4 2024).
  • Full‑Year Revenue: C$87.2 million (2025) vs. C$72.8 million (2024).
  • Clinic Revenue: C$20.7 million (Q4 2025) vs. C$17.5 million (Q4 2024); C$81.8 million (2025) vs. C$67.3 million (2024).
  • Non‑Clinic Revenue: C$1.4 million (Q4 2025) unchanged YoY; C$5.4 million (2025) vs. C$5.5 million (2024).
  • Adjusted EBITDA: C$1.0 million (Q4 2025) vs. C$0.9 million (Q4 2024); C$6.0 million (2025) vs. C$3.8 million (2024).
  • Gross Margin %: 18.3% (Q4 2025) vs. 19.2% (Q4 2024); 19.0% for both FY 2025 and FY 2024.
  • Capacity Utilization – Physician Shifts: 82% (FY 2025) vs. 75% (FY 2024).
  • Physical Capacity Utilization: 51% (FY 2025) vs. 48% (FY 2024); 52% Q4 2025 vs. 47% Q4 2024.
  • Liquidity & Debt: Cash & cash equivalents C$4.5 million; long‑term debt C$6.2 million (net debt C$1.7 million) as of Dec 31 2025.
  • Share Count: 56,306,787 basic shares; 62,169,211 fully diluted shares outstanding (Dec 31 2025).
  • Stock Options Grant: 295,000 options to two officers, exercisable at closing price on grant date, expiring March 31 2033; vest annually over 4 years.
  • Restricted Share Units Grant: 651,000 RSUs to two officers, fully vesting March 31 2030 with quarterly vesting (25% per year).
  • Investor Webinar: Presentation & Q&A on Thursday, March 26 2026 at 10:00 AM ET / 7:00 AM PT. Registration link provided.

Notable Quotes

  • “The team delivered another successful year, generating strong operating results in 2025… We entered 2026 in a very strong position…” – Joe Walewicz, CEO
  • “I want to thank Joe and our NeuPath team for building a strong foundation that will support our future growth…” – Stephen Lemieux, President & incoming CEO

All figures are presented in Canadian dollars unless otherwise noted.

Read the original news release →

More from Neupath Health Inc.

May 14, 2026 · 07:30

NeuPath Health Confirms Growth Trajectory Under New CEO Despite Margin Compression and Debt Settlement Risks

Earnings Apr 01, 2026 · 07:30

NEUPATH HEALTH ANNOUNCES PROPOSED SHARES FOR DEBT SETTLEMENT

Financings Mar 17, 2026 · 17:02

Neupath Health to release 2025 results March 26

Earnings Jan 26, 2026 · 17:51

Neupath Health appoints Lemieux as CEO

Other Jan 26, 2026 · 07:30

NEUPATH HEALTH ANNOUNCES EXECUTIVE LEADERSHIP CHANGES AS PART OF PLANNED TRANSITION, PRE-ANNOUNCES STRONG 2025 RESULTS

Other Nov 13, 2025 · 07:30

NEUPATH HEALTH REPORTS THIRD QUARTER 2025 RESULTS

Other